@article{c17ebf1e337f41e984640d015812cd22,
title = "iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders",
abstract = "It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and therapeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease.",
keywords = "AD, ALS, Alzheimer's disease, PD, Parkinson's disease, amyotrophic lateral sclerosis, disease modeling, drug repositioning, iPSCs, induced pluripotent stem cells, stratification",
author = "Hideyuki Okano and Satoru Morimoto",
note = "Funding Information: This work was supported by MEXT Grant-in-Aid, Japan, grant no. JP20H00485 and JP21H05273 to H.O., the Center Network for Realization Research Centers /Projects of Regenerative Medicine (the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells and the Acceleration Program for Intractable Diseases Research Utilizing Disease-specific iPS Cells) from AMED (grant no. 19bm0804003 , 20bm0804003 , 21bm0804003 ) to H.O., Practical Research Project for Rare / Intractable Diseases from AMED (grant no. 20ek0109492 , 21ek0109492 , 22ek0109492 ) to H.O., and Brain and Mind Research Promotion Program (Psychiatric/Neurological Disorder Mechanism Elucidation Project) from AMED (grant no. 21wm042500900 ) to H.O. Funding Information: We sincerely thank the members of my laboratory and collaborators for their contributions to the original works described in this review. We are also grateful to Drs. Wado Akamatsu, Kei-ichi Ishikawa, Daisuke Ito, Sumihiro Maeda, Shinichi Takahashi, and Ms. Emi Sen (medical student) in the Department of Physiology of Keio University School of Medicine, and Dr. Yasuhiro Murakawa in the Institute for the Advanced Study of Human Biology (ASHBi) in Kyoto University for their critical comments on the manuscript. We apologize for not being able to cite many relevant and excellent papers due to length limitations. This work was supported by MEXT Grant-in-Aid, Japan, grant no. JP20H00485 and JP21H05273 to H.O. the Center Network for Realization Research Centers/Projects of Regenerative Medicine (the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells and the Acceleration Program for Intractable Diseases Research Utilizing Disease-specific iPS Cells) from AMED (grant no. 19bm0804003, 20bm0804003, 21bm0804003) to H.O. Practical Research Project for Rare / Intractable Diseases from AMED (grant no. 20ek0109492, 21ek0109492, 22ek0109492) to H.O. and Brain and Mind Research Promotion Program (Psychiatric/Neurological Disorder Mechanism Elucidation Project) from AMED (grant no. 21wm042500900) to H.O. H.O. is a founder scientist and a Scientific Advisory Board member for SanBio Co. Ltd. and K Pharma Inc. Since this is a review article, we do not cover the patent information related to the original works cited here. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = feb,
day = "3",
doi = "10.1016/j.stem.2022.01.007",
language = "English",
volume = "29",
pages = "189--208",
journal = "Cell stem cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "2",
}
